Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2023 - Issue
Submit an article Journal homepage
381
Views
4
CrossRef citations to date
0
Altmetric
SHORT REPORT

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

Dave Singh1 Manchester University NHS Foundation Hospital Trust, the University of Manchester, Manchester, UKCorrespondence[email protected]
View further author information
,
Gerard J Criner2 Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USAView further author information
,
Alvar Agustí3 Respiratory Institute (Hospital Clinic), IDIBAPS, CIBERES, Catedra Salud Respiratoria (University of Barcelona), Barcelona, SpainView further author information
,
Mona Bafadhel4 School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UKView further author information
,
Johan Söderström5 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenORCID Iconhttps://orcid.org/0009-0002-0858-623XView further author information
ORCID Icon,
Gabriela Luporini Saraiva6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAORCID Iconhttps://orcid.org/0000-0002-2131-8013View further author information
ORCID Icon,
Yue Song6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Idlir Licaj7 Cytel Inc, Cambridge, MA, USAView further author information
,
Maria Jison6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Ubaldo J Martin6 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
&
Ioannis Psallidas8 Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
 show all
Pages 1595-1599 | Received 24 May 2023, Accepted 18 Jul 2023, Published online: 27 Jul 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.